Preventive Evolutionary Medicine of Cancers

Evolutionary Applications

Volumn 6, Issue 1, 2013, Pages 134-143

  Hochberg, Michael E ^a,b,c   Thomas, Frédéric ^c,d   Assenat, Eric ^e   Hibner, Urszula ^e  

^a UNIV MONTPELLIER   (France)

^b SANTA FE INSTITUTE   (United States)

^c Universite de Montpellier   (France)

^d University de Montpellier   (France)

^e INSTITUT DE GÉNÉTIQUE MOLÉCULAIRE DE MONTPELLIER   (France)

Author keywords

Cancer; Chemotherapy; Evolution; Evolutionary cell biology; Lifestyle; Microenvironment; Preventative evolutionary medicine; Prevention

Indexed keywords

EID: 84872802674     PISSN: 17524563     EISSN: 17524571     Source Type: Journal    
DOI: 10.1111/eva.12033     Document Type: Note

References (71)

1. Akkari, L., D. Grégoire, N. Floc'h, M. Moreau, C. Hernandez, Y. Simonin, A. R. Rosenberg et al. 2012. Hepatitis C viral protein NS5A induces EMT and participates in oncogenic transformation of primary hepatocyte precursors. Journal of hepatology 57:1021-1028.
2. Albini, A., and M. B. Sporn 2011. The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer 7:139-147.
3. Althuis, M. D., J. H. Fergenbaum, M. Garcia-Closas, L. A. Brinton, M. P. Madigan, and M. E. Sherm 2004. Etiology of hormone receptor-defined breast cancer: A systematic review of the literature. Cancer Epidemiology, Biomarkers & Prevention 13:1558-1568.
4. Ashworth, A. 2008. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. Journal of Clinical Oncology 26:3785-3790.
5. Balducci, L, and W. B. Ershler 2005. Cancer and ageing: a nexus at several levels. Nature Rev Cancer 5:655-662.
6. Bissell, M. J., and W. C. Hines 2011. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression Nature Medicine 17:320-329.
7. Bozic, I. T., H. Antal, H. Ohtsuki, H. Carter, D. Kim, S. Chen, R. Karchin et al. 2010. Accumulation of driver and passenger mutations during tumor progression. PNAS 107:18545-18550.
8. Bulliard, J. L., and F. Levi 2012. Mammography screening: time to reevaluate its impact? European Journal of Cancer Prevention 21:222-226.
9. Cejas, P., M. Lopez-Gomez, C. Aguayo, R. Madero, J. Moreno-Rubio, J. de Castro Carpeno, C. Belda-Iniesta 2012. et al. Analysis of the concordance in the EGFR pathway status between primary tumors and related metastases of colorectal cancer patients:implications for cancer therapy. Current Cancer Drug Targets 12:124-131.
10. Chalmers, A. J., M. Lakshman, N. Chan, and R. G. Bristow 2010. Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets. Seminars in Radiation Oncology 20:274-281.
11. Clappier, E., B. Gerby, F. Sigaux, M. Delord, F. Tourzri, L. Hernandez, P. Ballerini et al. 2011. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. The Journal of Experimental Medicine 208:653-661.
12. Crespi, B., and K. Summers 2005. Evolutionary biology of cancer. TRENDS in Ecology and Evolution 20:545-552.
13. Crook, J. M., C. J. O'Callaghan, G. Duncan, D. P. Dearnaley, C. S. Higano, E. M. Horwitz, E. Frymire et al. 2012. Intermittent androgen suppression for rising PSA level after radiotherapy. The New England Journal of Medicine 367:895-903.
14. Dang, C. V. 2012. Links between metabolism and cancer. Gene Development 26:877-890.
15. Deans, A. J., and S. C. West 2011. DNA interstrand crosslink repair and cancer. Nature Reviews Cancer 11:467-480.
16. DeGregori, J. 2011. Evolved tumor suppression: why are we so good at not getting cancer? Cancer Research 71:3739-3744.
17. Dobzhansky, T. 1946. Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura. Genetics 31:269-290.
18. Dunn, G. P., L. J. Old, and R. D. Schrieber 2004. The three Es of cancer immunoediting. Annual Review of Immunology 22:329-360.
19. Fang, J. S., R. D. Gillies, and R. A. Gatenby 2008. Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Seminars in Cancer Biology 18:330-337.
20. Finn, O. J. 2003. Cancer vaccines: between the idea and reality. Nature Rev Immun 3:630-641.
21. Folkman, J., and R. Kalluri 2004. Cancer without disease. Nature 427:785.
22. Frank, S. A., and M. R. Rosner 2012. Nonheritable cellular variability accelerates the evolutionary process of cancer. PLoS Biology 10:e1001296.
23. Gandon, S., and T. Day 2008. Evidences of parasite evolution after vaccination. Vaccine 26:C4-C7.
24. Garnett, M. J., E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur, K. W. Lau, P. Gerninger et al. 2012. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483:570-575.
25. Gatenby, R. A. 2011. Of cancer and cavefish. Nature Rev Can 11:237-238.
26. Gatenby, R. A., and R. J. Gillies 2008. A microenvironmental model of carcinogenesis. Nature Reviews Cancer 8:56-61.
27. Gatenby, R. A., J. Brown, and T. Vincent 2009. Lessons from applied ecology: Cancer control using an evolutionary double bind. Cancer Research 69:7499-7502.
28. Gerlinger, M., A. J. Rowan, S. Horswell, J. Larkin, D. Endesfelder, E. Gronroos, P. Martinez et al. 2012. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine 366:883-892.
29. Gillies, R. J., D. Verduzco, and R. A. Gatenby 2012. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer 12:487-493.
30. Greaves, M., and C. C. Maley 2012. Clonal evolution in cancer. Nature 481:306-313.
31. Hanahan, D., and R. A. Weinberg 2011. Hallmarks of cancer: the next generation. Cell 144:646-674.
32. Hemminki, K., R. Rawal, B. Chen, and L. J. Bermejo 2004. Genetic epidemiology of cancer: from families to heritable genes. International Journal of Cancer 111:944-950.
33. Hoelder, S., P. A. Clarke, and P. Workman 2012. Discovery of small molecule cancer drugs: successes, challenges and opportunities. Molecular Oncology 6:155-176.
34. Howlader, N., A. M. Noone, M. Krapcho, N. Neyman, R. Aminou, S. F. Altekruse, C. L. Kosary et al. (eds). 2012. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2009_pops09/ (based on November 2011 SEER data submission, posted to the SEER web site, April 2012).
35. Ibrahim-Hashim, A., H. H. Cornnell, D. Abrahams, M. Lloyd, M. Bui, R. J. Gillies, and R. A. Gatenby 2012. Systemic buffers inhibit carcinogenesis in TRAMP mice. Journal of Urology 188:624-631.
36. Johnston, L. A. 2009. Competitive interactions between cells: death, growth, and geography. Science 324:1679-1682.
37. Jones, S., W. D. Chen, G. Parmigiani, F. Diehl, N. Beerenwinkel, T. Antal, A. Traulsen et al. 2008. Comparative lesion sequencing provides insights into tumor evolution. PNAS 105:4283-4288.
38. Klotz, L. 2012. Cancer overdiagnosis and overtreatment. Current Opinion in Urology 22:203-209.
39. Komarova, N. L., and D. Wodarz 2005. Drug resistance in cancer: principles of emergence and prevention. PNAS 102:9714-9719.
40. Le Cesne, A., I. Ray-Coquard, B. N. Bui, A. Adenis, M. Rios, F. Bertucci, F. Duffaud et al. 2010. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. The Lancet Oncology 11:942-949.
41. Lengauer, C., K. W. Kinzler, and B. Vogelstein 1998. Genetic instabilities in human cancers. Nature 396:643-649.
42. Loeb, L. A. 2011. Human cancers express mutator phenotypes: origin, consequences and targeting. Nature Reviews Cancer 11:450-457.
43. Maley, C. C., B. J. Reid, and S. Forrest 2004. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Research 64:3414-3427.
44. Maley, C. C., E. Szabo, and B. J. Reid 2011. Somatic evolution in neoplastic progression and cancer prevention. In R. C. Fitzgerald ed. Pre-Invasive Disease: Pathogenesis and Clinical Management, Pp. 111-117 Springer Science + Business Media, New York.
45. Mariotto, A.B., K. R. Yabroff, Y. Shao1, E. J. Feuer, and M. L. Brown 2011. Projections of the cost of cancer care in the United States: 2010-2020. Journal of the National Cancer Institute 103:117-128.
46. de Martel, C., J. Ferlay, and S. Franceschi 2012. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. The Lancet Oncology 13:607-615. DOI:10.1016/S1470-2045(12)70137-7.
47. Medzhitov, R. D., S. Schneider, and M. P. Soares 2012. Disease tolerance as a defense strategy. Science 335:936-941.
48. Mendelsohn, J., U. Ringborg, and R. L. Schilsky 2012. Personalized cancer medicine - a strategy to counteract an increasing cancer challenge. Molecular Oncology 6:109-110.
49. Metcalfe, K. E., and S. A. Narod 2007. Breast cancer prevention in women with a BRCA1 or BRCA2 mutation. Open Medicine 1:184-190.
50. van Miltenburg, M. H., and J. Jonkers 2012. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches. Current Opinion in Genetics & Development 22:21-27.
51. de Murcia, G., and J. Menissier de Murcia 1994. Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends in Biochemical Sciences 19:172-176.
52. Palucka, K., H. Ueno, and J. Banchereau 2011. Recent developments in cancer vaccines. J Immunology 186:1325-1331.
53. Petrucelli, N., M. B. Daly, and G. L. Feldman 2010. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine 12:245-259.
54. Porporato, P. E., S. Dhup, R. K. Dadhich, T. Copetti, and P. Sonveaux 2011. Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review. Frontiers in Pharmacology 2:49.
55. Read, A. F., A. L. Graham, and L. Råberg 2008. Animal defenses against infectious agents: is damage control more important than pathogen control? PLoS Biology 6:e1000004.
56. Read, A. F., T. Day, and S. Huijben 2011. The evolution of drug resistance and the curious orthodoxy of aggressive chemotherapy. PNAS 108 (Suppl 2):10871-10877.
57. Reid, B. J., X. Li, P. C. Galipeau, and T. L. Vaughan 2010. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nature Reviews Cancer 10:87-101.
58. Rothwell, P. M., J. F. Price, F. G. R. Fowkes, A. Zanchetti, M. C. Roncaglioni, G. Tognoni, R. Lee et al. 2012. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379:1602-1612.
59. Rottenberg, S., M. A. Vollebergh, B. de Hoon, E. van der Burg, A. O. H. Nygren, S. A. L. Zander, P. W. B. Derksen et al. 2012. Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors. Cancer Research 72:2350-2361.
60. Sprouffske, K., J. W. Pepper, and C. C. Maley 2011. Accurate reconstruction of the temporal order of mutations in neoplastic progression. Cancer Prevention Research (Philadelphia, Pa.) 4:1135-1144.
61. Tsujimoto, Y., N. Ikegaki, and C. M. Croce 1987. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 2:3-7.
62. Tutt, A., M. Robson, J. E. Garber, S. M. Domchek, M. W. Audeh, J. N. Weitzel, M. Friedlander et al. 2010. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376:235-244.
63. Vacher, C., D. Bourguet, F. Rousset, C. Chevillon, and M. E. Hochberg 2003. Modelling the spatial configuration of refuges for a sustainable control of pests: a case study of Bt cotton. Journal of Evolutionary Biology 16:378-387.
64. Vogelstein, B., and K. W. Kinzler 1993. The multistep nature of cancer. Trends in Genetics 9:138-141.
65. Wallace, M. B., and R. Kiesslich 2010. Advances in endoscopic imaging of colorectal neoplasia. Gastroenterology 138:2140-2150.
66. Wang, X., H. Ouyang, Y. Yamamoto et al. 2011. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 145:1023-1035.
67. Welch, H. G., and W. C. Black 2010. Overdiagnosis in cancer. Journal of the National Cancer Institute 102:605-613.
68. Wodarz, A, and I. Nathke 2007. Cell polarity in development and cancer. Nature Cell Biology 9:1016-1024.
69. Wu, X., and S. M. Lippman 2011. An intermittent approach for cancer chemoprevention. Nature Reviews Cancer 11:879-885.
70. Yachida, S., S. Jones, I. Bozic, T. Antal, R. Leary, B. Fu, M. Kamiyama et al. 2010. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114-1117.
71. Zander, S. A., A. Kersbergen, E. van der Burg, N. de Water, O. Tellingen, S. Gunnarsdottir, J. E. Jaspers et al. 2010. Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan. Cancer Research 70:1700-1710.